Description

Docetaxel (docetaxel) concentrate for infusions 20 mg/ml. 4 ml. (80 mg.) vial №1

Ingredients:

Each vial contains 80 mg of Docetaxel in a 4 ml concentrate for infusion.

Dosage:

The dosage of Docetaxel should be determined by a healthcare provider based on the patient’s condition, weight, and other medications being taken. It is typically administered intravenously over 1 hour every 3 weeks.

Indications:

Docetaxel is indicated for the treatment of various types of cancers, including breast cancer, non-small cell lung cancer, prostate cancer, and others. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications:

Patients with a history of severe hypersensitivity reactions to Docetaxel or polysorbate 80 should not use this medication. It is important to discuss any allergies or medical conditions with your healthcare provider before starting treatment.

Directions:

Docetaxel should only be administered by a healthcare provider in a clinical setting due to the risk of serious side effects. It is important to follow all instructions for preparation and infusion carefully.

Scientific Evidence:

Docetaxel has been extensively studied in clinical trials for its efficacy in treating various types of cancer. Research has shown that Docetaxel, as a microtubule inhibitor, disrupts the normal function of microtubules essential for cell division, ultimately leading to cell death in cancer cells. Studies have demonstrated its effectiveness in improving survival rates and reducing tumor size in patients with advanced cancers.

Additional Information:

In addition to its anti-cancer effects, Docetaxel has also been investigated for its potential in combination therapies and as an adjuvant treatment. Research suggests that combining Docetaxel with other chemotherapy agents or targeted therapies can enhance its efficacy and broaden its application in different cancer types. It is essential for patients to discuss the potential benefits and risks of Docetaxel treatment with their healthcare team.

Overall, Docetaxel (docetaxel) concentrate for infusions 20 mg/ml. 4 ml. (80 mg.) vial №1 is a crucial component in the treatment of various cancers, backed by substantial scientific evidence and clinical trials supporting its efficacy and safety profile.